Paclitaxel and Bavituximab in Treating Patients With HER2-Negative Metastatic Breast Cancer

Inclusion Criteria:

* Written informed consent has been obtained
* Life expectancy of at least 3 months
* Histologically or cytologically confirmed, Her-2 negative breast cancer with evidence of metastatic disease
* Measurable or evaluable disease by Response Evaluation Criteria In Solid Tumors (RECIST)
* Eastern Cooperative Oncology Group (ECOG) Performance Status =\< 2
* Adequate hematologic function (absolute neutrophil count \[ANC\] \>= 1,500 cells/uL; hemoglobin \>= 9 g/dL; platelets \>= 100,000/uL and =\< 500,000/uL)
* Adequate renal function (serum creatinine =\< 1.5 mg/dL or calculated creatinine clearance \>= 60 ml/min)
* Adequate hepatic function (total or direct bilirubin =\< Upper Limit of Normal (ULN), Alk Phos =\< 4 x ULN)
* Prothrombin time international normalized ratio within institutional normal limits
* Activated partial thromboplastin time =\< 1.5 x ULN
* New York Heart Association classification I or II
* Female patients must have a negative urine pregnancy test at prestudy (not applicable to patients with bilateral oophorectomy and/or hysterectomy or to those patients who are postmenopausal)

Exclusion Criteria:

* Known history of bleeding diathesis or coagulopathy (e.g., von Willebrand Disease, Hemophilia)
* Any current evidence of clinically significant active bleeding
* Any history of significant thromboembolic events (i.e., deep vein thrombosis or pulmonary thromboembolism) within the last five years or requirement for ongoing therapy with oral or parenteral anticoagulants; central venous catheter-related thrombosis \> 12 months ago and low dose anticoagulants to maintain patency of lines are allowed; patients taking anticoagulants (e.g., prophylactic heparin or enoxaparin) are required to observe the washout period of 1 week prior to study drug infusion on Study Day 1
* Concurrent hormone therapy (i.e., estrogen contraceptives, hormone replacement, anti-estrogen); patients taking concurrent hormone therapy are required to observe the washout period of 2 weeks prior to study drug infusion on Study Day 1
* Grade 2 or higher peripheral neuropathy (e.g., numbness, tingling, and/or pain in distal extremities)
* More than one prior chemotherapy regimen for metastatic disease (prior adjuvant chemotherapy or any number of prior hormonal therapies are allowed)
* Chemotherapy, immunotherapy or radiotherapy within 2 weeks of Study Day 1 or not having recovered from significant treatment-related side effects due to agents administered previously; patients who have receive nitrosoureas and mitomycin C therapy are required to observe the washout period of 6 weeks prior to study drug infusion on Study Day 1
* Allergy to polysorbate 80 or drugs containing polyoxyethylated castor oil (e.g. cyclosporine)
* Symptomatic or clinically active Central Nervous System (CNS) disease
* Major surgery within 4 weeks of Study Day 1
* Female patients pregnant or nursing
* All patients of reproductive potential must agree to use appropriate non-hormonal form of contraception
* Uncontrolled intercurrent disease (e.g., diabetes, hypertension, thyroid disease)
* Any history of angina pectoris, coronary artery disease or cerebrovascular accident, or transient ischemic attack
* A history of any condition requiring anti-platelet therapy (e.g., phosphodiesterase inhibitors, adenosine diphosphate receptor antagonists) with the exception of general cardiovascular prophylaxis with aspirin
* Cardiac arrhythmia requiring medical therapy
* Serious non-healing wound (including wound healing by secondary intention, ulcer, or bone fracture)
* Requirement for chronic daily steroid use
* Known chronic infection with Human Immunodeficiency Virus (HIV), Hepatitis B Virus (HBV), or Hepatitis C Virus (HCV)